Fatty acid binding protein 5 inhibition attenuates pronociceptive cytokine/chemokine expression and suppresses osteoarthritis pain : A comparative human and rat study
Copyright © 2023 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved..
OBJECTIVE: Osteoarthritis (OA) is often accompanied by debilitating pain that is refractory to available analgesics due in part to the complexity of signaling molecules that drive OA pain and our inability to target these in parallel. Fatty acid binding protein 5 (FABP5) is a lipid chaperone that regulates inflammatory pain; however, its contribution to OA pain has not been characterized.
DESIGN: This combined clinical and pre-clinical study utilized synovial tissues obtained from subjects with end-stage OA and rats with monoiodoacetate-induced OA. Cytokine and chemokine release from human synovia incubated with a selective FABP5 inhibitor was profiled with cytokine arrays and ELISA. Immunohistochemical analyses were conducted for FABP5 in human and rat synovium. The efficacy of FABP5 inhibitors on pain was assessed in OA rats using incapacitance as an outcome. RNA-seq was then performed to characterize the transcriptomic landscape of synovial gene expression in OA rats treated with FABP5 inhibitor or vehicle.
RESULTS: FABP5 was expressed in human synovium and FABP5 inhibition reduced the secretion of pronociceptive cytokines (interleukin-6 [IL6], IL8) and chemokines (CCL2, CXCL1). In rats, FABP5 was upregulated in the OA synovium and its inhibition alleviated incapacitance. The transcriptome of the rat OA synovium exhibited >6000 differentially expressed genes, including the upregulation of numerous pronociceptive cytokines and chemokines. FABP5 inhibition blunted the upregulation of the majority of these pronociceptive mediators.
CONCLUSIONS: FABP5 is expressed in the OA synovium and its inhibition suppresses pronociceptive signaling and pain, indicating that FABP5 inhibitors may constitute a novel class of analgesics to treat OA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Osteoarthritis and cartilage - 32(2024), 3 vom: 01. Feb., Seite 266-280 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gordon, Chris [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Analgesics |
|---|
| Anmerkungen: |
Date Completed 23.02.2024 Date Revised 23.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.joca.2023.11.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365270989 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365270989 | ||
| 003 | DE-627 | ||
| 005 | 20240229143907.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.joca.2023.11.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1303.xml |
| 035 | |a (DE-627)NLM365270989 | ||
| 035 | |a (NLM)38035977 | ||
| 035 | |a (PII)S1063-4584(23)00989-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gordon, Chris |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fatty acid binding protein 5 inhibition attenuates pronociceptive cytokine/chemokine expression and suppresses osteoarthritis pain |b A comparative human and rat study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2024 | ||
| 500 | |a Date Revised 23.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a OBJECTIVE: Osteoarthritis (OA) is often accompanied by debilitating pain that is refractory to available analgesics due in part to the complexity of signaling molecules that drive OA pain and our inability to target these in parallel. Fatty acid binding protein 5 (FABP5) is a lipid chaperone that regulates inflammatory pain; however, its contribution to OA pain has not been characterized | ||
| 520 | |a DESIGN: This combined clinical and pre-clinical study utilized synovial tissues obtained from subjects with end-stage OA and rats with monoiodoacetate-induced OA. Cytokine and chemokine release from human synovia incubated with a selective FABP5 inhibitor was profiled with cytokine arrays and ELISA. Immunohistochemical analyses were conducted for FABP5 in human and rat synovium. The efficacy of FABP5 inhibitors on pain was assessed in OA rats using incapacitance as an outcome. RNA-seq was then performed to characterize the transcriptomic landscape of synovial gene expression in OA rats treated with FABP5 inhibitor or vehicle | ||
| 520 | |a RESULTS: FABP5 was expressed in human synovium and FABP5 inhibition reduced the secretion of pronociceptive cytokines (interleukin-6 [IL6], IL8) and chemokines (CCL2, CXCL1). In rats, FABP5 was upregulated in the OA synovium and its inhibition alleviated incapacitance. The transcriptome of the rat OA synovium exhibited >6000 differentially expressed genes, including the upregulation of numerous pronociceptive cytokines and chemokines. FABP5 inhibition blunted the upregulation of the majority of these pronociceptive mediators | ||
| 520 | |a CONCLUSIONS: FABP5 is expressed in the OA synovium and its inhibition suppresses pronociceptive signaling and pain, indicating that FABP5 inhibitors may constitute a novel class of analgesics to treat OA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cytokine | |
| 650 | 4 | |a FABP5 | |
| 650 | 4 | |a Fatty acid binding protein 5 | |
| 650 | 4 | |a Osteoarthritis | |
| 650 | 4 | |a Pain | |
| 650 | 4 | |a Transcriptomics | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Chemokines |2 NLM | |
| 650 | 7 | |a Analgesics |2 NLM | |
| 650 | 7 | |a Fatty Acid-Binding Proteins |2 NLM | |
| 650 | 7 | |a FABP5 protein, human |2 NLM | |
| 700 | 1 | |a Trainor, James |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Rohan J |e verfasserin |4 aut | |
| 700 | 1 | |a Studholme, Keith |e verfasserin |4 aut | |
| 700 | 1 | |a Gelman, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Doswell, Faniya |e verfasserin |4 aut | |
| 700 | 1 | |a Sadar, Faisal |e verfasserin |4 aut | |
| 700 | 1 | |a Giovannetti, Allessio |e verfasserin |4 aut | |
| 700 | 1 | |a Gershenson, Josh |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Ayesha |e verfasserin |4 aut | |
| 700 | 1 | |a Nicholson, James |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, ZeYu |e verfasserin |4 aut | |
| 700 | 1 | |a Spurgat, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Shao-Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hehe |e verfasserin |4 aut | |
| 700 | 1 | |a Ojima, Iwao |e verfasserin |4 aut | |
| 700 | 1 | |a Carlson, David |e verfasserin |4 aut | |
| 700 | 1 | |a Komatsu, David E |e verfasserin |4 aut | |
| 700 | 1 | |a Kaczocha, Martin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Osteoarthritis and cartilage |d 1993 |g 32(2024), 3 vom: 01. Feb., Seite 266-280 |w (DE-627)NLM075127784 |x 1522-9653 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2024 |g number:3 |g day:01 |g month:02 |g pages:266-280 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.joca.2023.11.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2024 |e 3 |b 01 |c 02 |h 266-280 | ||